Tobias Neef1, Stephen D Miller2. 1. Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, 6-713 Tarry Building, 303 E. Chicago Avenue, Chicago, IL, 60611, USA. 2. Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, 6-713 Tarry Building, 303 E. Chicago Avenue, Chicago, IL, 60611, USA. s-d-miller@northwestern.edu.
Abstract
PURPOSE OF REVIEW: The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases are typically treated with broad immunosuppression, but this has multiple disadvantages. Induction of antigen-specific tolerance is preferable. The application of nanomedicine to the problem of T1D can take different forms, but one promising way is the development of tolerogenic nanoparticles, the aim of which is to mitigate the islet-destroying autoimmunity. We review the topic and highlight recent strategies to produce tolerogenic nanoparticles for the purpose of treating T1D. RECENT FINDINGS: Several groups are making progress in applying tolerogenic nanoparticles to rodent models of T1D, while others are using nanotechnology to aid other potential T1D treatments such as islet transplant and islet encapsulation. The strategies behind how nanoparticles achieve tolerance are varied. It is likely the future will see even greater diversity in tolerance induction strategies as well as a greater focus on how to translate this technology from preclinical use in mice to treatment of T1D in humans.
PURPOSE OF REVIEW: The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases are typically treated with broad immunosuppression, but this has multiple disadvantages. Induction of antigen-specific tolerance is preferable. The application of nanomedicine to the problem of T1D can take different forms, but one promising way is the development of tolerogenic nanoparticles, the aim of which is to mitigate the islet-destroying autoimmunity. We review the topic and highlight recent strategies to produce tolerogenic nanoparticles for the purpose of treating T1D. RECENT FINDINGS: Several groups are making progress in applying tolerogenic nanoparticles to rodent models of T1D, while others are using nanotechnology to aid other potential T1D treatments such as islet transplant and islet encapsulation. The strategies behind how nanoparticles achieve tolerance are varied. It is likely the future will see even greater diversity in tolerance induction strategies as well as a greater focus on how to translate this technology from preclinical use in mice to treatment of T1D in humans.
Entities:
Keywords:
Diabetogenic antigens; PLG nanoparticles; Regulatory T cells; Tolerance; Type 1 diabetes
Authors: Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Brian D Stadinski; Thomas Delong; Nichole Reisdorph; Richard Reisdorph; Roger L Powell; Michael Armstrong; Jon D Piganelli; Gene Barbour; Brenda Bradley; Frances Crawford; Philippa Marrack; Sushil K Mahata; John W Kappler; Kathryn Haskins Journal: Nat Immunol Date: 2010-02-07 Impact factor: 25.606
Authors: Mihir Shah; Maria C Edman; Srikanth R Janga; Pu Shi; Jugal Dhandhukia; Siyu Liu; Stan G Louie; Kathleen Rodgers; J Andrew Mackay; Sarah F Hamm-Alvarez Journal: J Control Release Date: 2013-07-25 Impact factor: 9.776
Authors: Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: S Marin-Gallen; X Clemente-Casares; R Planas; I Pujol-Autonell; J Carrascal; J Carrillo; R Ampudia; J Verdaguer; R Pujol-Borrell; F E Borràs; M Vives-Pi Journal: Clin Exp Immunol Date: 2009-12-17 Impact factor: 4.330
Authors: Florian Leuschner; Partha Dutta; Rostic Gorbatov; Tatiana I Novobrantseva; Jessica S Donahoe; Gabriel Courties; Kang Mi Lee; James I Kim; James F Markmann; Brett Marinelli; Peter Panizzi; Won Woo Lee; Yoshiko Iwamoto; Stuart Milstein; Hila Epstein-Barash; William Cantley; Jamie Wong; Virna Cortez-Retamozo; Andita Newton; Kevin Love; Peter Libby; Mikael J Pittet; Filip K Swirski; Victor Koteliansky; Robert Langer; Ralph Weissleder; Daniel G Anderson; Matthias Nahrendorf Journal: Nat Biotechnol Date: 2011-10-09 Impact factor: 54.908
Authors: Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-11-20 Impact factor: 14.307
Authors: Zoe Hunter; Derrick P McCarthy; Woon Teck Yap; Christopher T Harp; Daniel R Getts; Lonnie D Shea; Stephen D Miller Journal: ACS Nano Date: 2014-02-27 Impact factor: 15.881
Authors: Sahil Shah; Saeed Daneshmandi; Kevin R Hughes; Shuangjin Yu; Angela M Bedoya; Lonnie D Shea; Xunrong Luo Journal: Biomaterials Date: 2019-05-01 Impact factor: 12.479
Authors: Christopher Kopan; Tori Tucker; Michael Alexander; M Rezaa Mohammadi; Egest J Pone; Jonathan Robert Todd Lakey Journal: Front Immunol Date: 2018-06-12 Impact factor: 7.561
Authors: Tobias Neef; Igal Ifergan; Sara Beddow; Pablo Penaloza-MacMaster; Kathryn Haskins; Lonnie D Shea; Joseph R Podojil; Stephen D Miller Journal: Cells Date: 2021-12-07 Impact factor: 7.666